Escribano-Subias P, López R, Almenar L, et al. - Researchers undertook this retrospective, observational study to report change over time in REVEAL (Registry to Evaluate Early and Long-term PAH Disease Management) risk score among incident and prevalent patients who were given macitentan [a dual endothelin receptor antagonist indicated for the long-term treatment of pulmonary arterial hypertension (PAH)] for the first time. This study included adult patients suffering from idiopathic/heritable PAH or PAH related to connective tissue disorders or congenital heart disease managed with macitentan for ≥ 6-month follow-up. At the initiation of macitentan and after ≥ 6-month, the REVEAL risk score and risk strata were calculated among patients with ≥ 7 out of 12 valid REVEAL components. Findings revealed that macitentan brought about improvement in the REVEAL risk strata as well as score in both incident and prevalent PAH patients, and in all patients irrespective of the therapy strategy. Also, at least 6-month follow-up revealed significant improvement in some of REVEAL components, including WHO functional class, brain natriuretic peptide/N-terminal pro-brain natriuretic peptide, pulmonary vascular resistance, and 6-min walk test, in relation to treatment with macitentan.